Skip to main content
. 2014 Dec 6;9:275. doi: 10.1186/s13014-014-0275-6

Table 4.

Hypofractionated IMRT/IGRT trials

Reference Study design Number of patients Fractionation (total dose/ singel dose/fractions) EQD for tumor α/β-ratio 1.4Gy EQD for normal tussues α/β-ratio 3Gy IGRT Follow-up Acute GU toxicitiy Late GU toxicity Acute GI toxicity Late GI toxicity Therapeutic outcomes
Arcangeli, G. [14] Phase III prospective 168 pat. Arm I: 80Gy/2Gy/40 fractions, ArmII: 62Gy/3.1Gy/20 fractions, 4x/week. 82.1Gy 74.2Gy daily portal imaging 70 months - Arm I: 16% ≥ II° GI, Arm II: 11% ≥ II° GI., at 3 years. - Arm I: 17% ≥ II° GI, Arm II: 14% ≥ II° GI, at 3 years. Hypofraction-RT is not inferior to conventional RT.
Dearnaley, D. [15] Phase III prospective Arm I: 153 pat. 74Gy; Arm II 153 pat. 60Gy and 151 pat. 57Gy. Arm I: 74Gy/2Gy/37 fx; Arm II: 57-60Gy/3Gy/19-20 fx. Arm II: 73.8/77.6Gy Arm II: 68.4/72Gy no 50.5 months - At 2 years, 3 pat. (2 · 2%) in 74Gy group, 3 (2 · 2%) in 60Gy group, and 0 in 57Gy group ≥ II° GU. - At 2 years, 6 pat. (4 · 3%) in Arm I ≥ II° RTOG, 5 pat. (3 · 6%) in 60Gy group, 2 (1 · 4%) in 57Gy group. -
Pollack, A. [16] Phase III prospective 307 (ASTRO Update 2011) Arm I: 76Gy/2Gy/28 fx; Arm II: 70.2Gy/2.7Gy/26 fx. Arm II: 84.7Gy Arm II: 80Gy. no 5 years Arm I: 54% > II°; 2% > III°; Arm II: 40% > II°; 8% > III°. Arm I: 8.3%; Arm II: 18.3% at 5 years Arm I: 8% ≥ II°; Arm II: 18% ≥ II° 4.5% ≥ II° GI. biochem. recurrence 21.5% vs. 21.9% at 5 years
McDonald, A.M. [31] Retrospective 57 PORT and 31 WPRT 70Gy/2.5Gy/ 28 fractions 80.3Gy 77Gy CBCT daily 41 months 18/31(58%) in PORT, 28/57(49%) in WPRT ≥ II° 4/57(7%)in WPRT, 0% in PORT ≥ III° GU 7/31(23%) in PORT, 23/57 (40%) in WPRT ≥ II° GI 0% in PORT, 10/57(18%) in WPRT ≥ II° GI -
Adkinson, J.B. [29] Phase I prospective 53 pat. 70Gy/2.5Gy/28 fractions 80.3Gy 77Gy yes 25.4 months 20/53(38%) ≥ II° GU 14/53(27%) ≥ II° GU 17/53(32%) ≥ II° GI 4/53(8%) ≥ II° GI biochem. control (nadir +2) 81.2 ± 6.6%.
Jereczek-Fossa, B.A. [51] Prospective longitudinal follow-up 337 pat. cT1-2, 40.9% low-risk; 43.3% intermed-risk; 14.2% high-risk. 70.2Gy/2.7Gy/26 frations 84.7Gy 80Gy BAT 72%, stereo X-ray 16.4%, CBCT 11.9% pat. 19 months 35% ≥ II° GU, 6.2% ≥ III° GU. 10.4% ≥ II° GU, 1.6% ≥ III° GU. 11.3% ≥ II° GI, 1.2% ≥ III° GI. 7.5% ≥ II° GI, 1.3% ≥ III° GI. -
Kupelian, P. A. [18] Retrospective 770 pat, 34% low-risk, 28% intermed.-risk, 38% high-risk D'Amico criterien. 70Gy/2.5Gy/28 fractions, but mean target dose was 75.3Gy at 2.7Gy! 80.3Gy with 1.4Gy α/β-ratio (83.8Gy with 3.5Gy α/β-ratio in publication) 77Gy IGRT with BAT tranabdominal ultrasound 45 months 33% Pat. 0°, 48% I°, 18% II°, 1% III° RTOG 90.5% pat. 0°, 4.3% I°, 5.1% II°, 0.1%(1 pat.) III° RTOG 51% pat. 0°, 40% I°, 9% II° RTOG 89.6% pat. 0°, 5.9% I°, 3.1% II°, 1.4% ≥ III° RTOG At 5 years 94%, 83%, 72% for low-/intermed./high-risk respectively (Nadir + 2 ng/ml)
Quon, H. [33] Prospective phase I-II 97 pat. High-risk 67.5Gy/2.7Gy/25 fractions 81.4Gy 77Gy IGRT with gold marker 39 months median 8% pat. 0°, 50% I°, 39% II°, 4% III° CTCAE 82% pat. 0°, 9% I°, 5% II°, 3% III°, 1% IV°. 4% pat. 0°, 59% I°, 37% II° 54% pat. 0°, 40% I°, and 7% II° 4 year bFFS 90.5%.
Martin, J. [40] Prospective phase I-II 92 pat., mainly intermed./low risk 60Gy/3Gy/20 fractions 77.6Gy 72Gy IGRT with gold marker 38 months median 32% pat. 0°, 43% I°, 25% II° RTOG 90% pat. 0°, 7% I°, 3% II° RTOG 66% pat. 0°, 22% I°, 11% II°, 1% IV° RTOG 93% pat. 0°, 2% I°, 4% II° RTOG 3 year biochemical control 76%.